Belite Bio, Inc (BLTE)
NASDAQ: BLTE · Real-Time Price · USD
73.19
+6.29 (9.40%)
Sep 17, 2025, 3:50 PM EDT - Market open
Belite Bio Employees
Belite Bio had 25 employees as of December 31, 2024. The number of employees increased by 5 or 25.00% compared to the previous year.
Employees
25
Change (1Y)
5
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$916,480
Market Cap
2.40B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25 | 5 | 25.00% |
| Dec 31, 2023 | 20 | 4 | 25.00% |
| Dec 31, 2022 | 16 | 4 | 33.33% |
| Dec 31, 2021 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BLTE News
- 5 days ago - Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease - GlobeNewsWire
- 9 days ago - Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors - GlobeNewsWire
- 5 weeks ago - Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 5 weeks ago - Belite Bio Announces Registered Direct Offering of $15 Million - GlobeNewsWire
- 2 months ago - Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy - GlobeNewsWire
- 4 months ago - Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease - GlobeNewsWire
- 4 months ago - Belite Bio: Investors Face Tricky Decision Ahead Of Key STGD1 Study Readout - Seeking Alpha